What is Mana.bio?
Based in Tel Aviv, Israel, Mana.bio leverages artificial intelligence to discover and optimize novel, customizable LNPs. These advanced delivery systems are designed for the targeted administration of nucleic acid-based therapeutics and vaccines, addressing a critical challenge in modern medicine: ensuring that therapeutic agents reach their intended tissues with high specificity and minimal off-target effects. The company's AI platform aims to accelerate the development of next-generation treatments by enhancing the efficacy and safety of gene therapies, RNA-based drugs, and vaccines.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $19.5M across 1 funding round:
Angel/Seed
$19.5M
Angel/Seed (2023): $19.5M with participation from LionBird, Andreessen Horowitz, and The NFX
Key Investors in Mana.bio
LionBird
LionBird (Ventures) Ltd. invests in innovative health-tech startups that aim to transform the healthcare landscape through technology. They provide pre-scale capital and support to teams dedicated to improving healthcare solutions.
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies. The company is headquartered in Menlo Park, California.
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors. Their investment areas include gaming, generative AI, proptech, space, fintech, marketplaces, and crypto.
What's next for Mana.bio?
With this recent major strategic investment, Mana.bio is poised to accelerate its research and development initiatives, further refine its AI-driven LNP discovery platform, and potentially expand its therapeutic applications. The enterprise-level funding suggests a transition towards scaling operations and advancing its pipeline towards clinical validation. Investors such as LionBird, Andreessen Horowitz, and The NFX are backing Mana.bio, indicating a strong belief in its potential to disrupt the biopharmaceutical industry by enabling more effective and targeted delivery of advanced therapies.
See full Mana.bio company page
